肌少症性肥胖与 2 型糖尿病患者的大量白蛋白尿有关:一项横断面研究。
Sarcopenic obesity is associated with macroalbuminuria in patients with type 2 diabetes: a cross-sectional study.
机构信息
Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 621-8585, Japan.
出版信息
Endocr J. 2021 Jul 28;68(7):781-789. doi: 10.1507/endocrj.EJ20-0655. Epub 2021 Mar 17.
Sarcopenia is associated with the risk of albuminuria in patients with type 2 diabetes mellitus (T2DM), and obesity is a risk factor for proteinuria. However, the association between sarcopenic obesity and diabetic nephropathy, including albuminuria, in patients with T2DM has not been reported. The study included 206 men and 163 women with T2DM who participated in the KAMOGAWA-DM cohort, which investigating the natural history of diabetes since 2014. Sarcopenia was defined as having both low skeletal muscle mass index (SMI, kg/m) (<7.0 kg/m for men and <5.7 kg/m for women) and low handgrip strength (<28 kg for men and <18 kg for women). Obesity was diagnosed by the percentage of body fat (>30% for men and >35% for women). The patient was said to have sarcopenic obesity if he/she had both sarcopenia and obesity. Urinary albumin excretion of patients with sarcopenic obesity was higher than that of patients without sarcopenic obesity (median [interquartile range]: 342.0 [41.8-467.5] vs. 21.0 [9.0-75.4] mg/g Cr, p = 0.016). Additionally, sarcopenic obesity was associated with the presence of macroalbuminuria, compared with non-sarcopenic obesity (adjusted odds ratio 6.92 [95% confidence interval:1.63-29.4], p = 0.009). Adjusted odds ratios of sarcopenic obesity, sarcopenia only, and obesity only for the presence of macroalbuminuria were 6.52 (1.47-28.8, p = 0.014), 1.29 (0.45-3.71, p = 0.638), and 0.78 (0.38-1.58, p = 0.482), respectively, compared with neither sarcopenia nor obesity. This study indicated that sarcopenic obesity is associated with albuminuria, especially macroalbuminuria, in Japanese patients with T2DM.
肌少症与 2 型糖尿病(T2DM)患者发生白蛋白尿的风险相关,肥胖是蛋白尿的一个危险因素。然而,关于 T2DM 患者肌少性肥胖与包括白蛋白尿在内的糖尿病肾病之间的关系尚未见报道。本研究纳入了 206 名男性和 163 名女性 T2DM 患者,这些患者参加了 KAMOGAWA-DM 队列研究,该研究自 2014 年开始对糖尿病的自然史进行了调查。肌少症的定义为同时存在低骨骼肌质量指数(SMI,kg/m)(男性<7.0kg/m,女性<5.7kg/m)和低握力(男性<28kg,女性<18kg)。肥胖则通过体脂百分比(男性>30%,女性>35%)来诊断。如果患者同时存在肌少症和肥胖,则称之为肌少性肥胖。与无肌少性肥胖的患者相比,肌少性肥胖患者的尿白蛋白排泄量更高(中位数[四分位间距]:342.0[41.8-467.5]vs.21.0[9.0-75.4]mg/gCr,p=0.016)。此外,与非肌少性肥胖相比,肌少性肥胖与大量白蛋白尿的存在相关(校正比值比 6.92[95%可信区间:1.63-29.4],p=0.009)。校正比值比显示,肌少性肥胖、单纯肌少症和单纯肥胖对大量白蛋白尿的存在的比值分别为 6.52(1.47-28.8,p=0.014)、1.29(0.45-3.71,p=0.638)和 0.78(0.38-1.58,p=0.482),与既非肌少症也非肥胖相比。本研究表明,在日本的 T2DM 患者中,肌少性肥胖与白蛋白尿,尤其是大量白蛋白尿相关。